Efficacy, Safety of T2769 in Dry Eye Disease

N/ACompletedNCT03830359

Laboratoires Thea62 enrolled

Overview

Efficacy of T2769 in Dry Eye Desease

Multicenter and open study

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Dry Eye Syndrome

Interventions

T2769OTHER

At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed and dated informed consent * Male or female aged from ≥ 18 years old * Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study screening Exclusion Criteria: * Best far corrected visual acuity ≤ 2/10 * Severe blepharitis Severe dry eye

Locations (3)

Hôpital Universitaire Tahar Sfar

Mahdia, Tunisia

"Hôpital Universitaire Fattouma Bourguiba

Monastir, Tunisia

"Hôpital de Forces de Sécurité Intérieure La Marsa

Tunis, Tunisia

Outcomes

Primary Outcomes

Ocular Symptomatology

Change from baseline in ocular symptomatology on a Visual Analog Scale (0=No discomfort and 100=Maximal discomfort) at Day 42.

Time frame: Baseline and Day 42

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.